Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib Plus Capecitabine|DRUG: Lapatinib Plus Capecitabine
Sponsor: Jiangsu HengRui Medicine Co., Ltd.